CLINICAL RESEARCH
Profiling oxidative stress markers and cardiovascular complications in chronic kidney disease patients supplemented with vitamin E
1
Nephrology Service, Hussein Dey Hospital, Algiers, Algeria
2
Laboratory of Oxidative Stress, Kidney and Associated Complications,
University of Algiers, Algeria
3
Hospital CHU Parnet, University of Algiers, Algeria
4
Department of Biomedical Sciences. Institute of Veterinary Sciences,
University of Tiaret, Tiaret, Algeria
5
Department of Pneumology, CHU Beni Messous, Algeria
6
Department of Biochemistry, Hospital of CPMC, Faculty of Pharmacy, Algiers, Algeria
7
Department of Orthopaedic Surgery, Hospital of Bejaia, Faculty of Medicine, Bejaia, Algeria
8
Department of Pharmacology, Pastor Institute, Faculty of Pharmacy, Algiers, Algeria
Submission date: 2023-10-24
Final revision date: 2024-07-19
Acceptance date: 2024-08-18
Publication date: 2024-10-15
Corresponding author
Leila Azouaou
Laboratory of Oxidative Stress, Kidney and Associated Complications, University of Algiers, Algeria, Phone: 00213661790913
Laboratory of Oxidative Stress, Kidney and Associated Complications, University of Algiers, Algeria, Phone: 00213661790913
Arch Med Sci Atheroscler Dis 2024;9(1):183-192
KEYWORDS
TOPICS
ABSTRACT
Introduction:
Cardiovascular diseases are common complications in chronic kidney disease (CKD). Oxidative stress associated with renal and metabolic dysfunctions is one of the cardiovascular complications (CVC) in haemodialysis patients. The aim of the present study is to analyse the oxidative stress markers in CDK patients supplemented with antioxidants and vitamin E, with monitoring of CVC.
Material and methods:
This was a cross-sectional study conducted on 99 subjects. CKD patients received oral supplementation of vitamin E (300 mg/day) for 2 years. Oxidative stress markers, nitric oxide (NO); myeloperoxidase (MPO); oxidized low-density lipoprotein (LDLox); malondialdehyde (MDA) and glutathione were measured before and after the vitamin treatment.
Results:
NO (62.62 ±2.80 µmol/l), LDLox (10.55 ±4.62 µmol/l), MDA (6.11 ±2.83 µmol/l) and MPO (53.35 ±3.82 UI/ml) were overconcentrated, while glutathione (62.09 ±4.15 UI/ml) was less concentrated in CKD patients with cardiovascular complications, compared to those without cardiovascular complications (67.08 ±1.90 µmol/l, 31.18 ±5.25 µmol/l, 16 ±6.47 µmol/l, 57.00 ±7.24 UI/ml, 43.09 ±3.33 UI/ml, respectively). After 2 years of vitamin E treatment, the overall cardiovascular complications were not significantly decreased.
Conclusions:
These results showed that oral complementation with vitamin E did not affect the occurrence of cardiovascular complications associated with CKD. These findings may pave the way for future innovative strategies for antioxidant supplementation in CKD patients.
Cardiovascular diseases are common complications in chronic kidney disease (CKD). Oxidative stress associated with renal and metabolic dysfunctions is one of the cardiovascular complications (CVC) in haemodialysis patients. The aim of the present study is to analyse the oxidative stress markers in CDK patients supplemented with antioxidants and vitamin E, with monitoring of CVC.
Material and methods:
This was a cross-sectional study conducted on 99 subjects. CKD patients received oral supplementation of vitamin E (300 mg/day) for 2 years. Oxidative stress markers, nitric oxide (NO); myeloperoxidase (MPO); oxidized low-density lipoprotein (LDLox); malondialdehyde (MDA) and glutathione were measured before and after the vitamin treatment.
Results:
NO (62.62 ±2.80 µmol/l), LDLox (10.55 ±4.62 µmol/l), MDA (6.11 ±2.83 µmol/l) and MPO (53.35 ±3.82 UI/ml) were overconcentrated, while glutathione (62.09 ±4.15 UI/ml) was less concentrated in CKD patients with cardiovascular complications, compared to those without cardiovascular complications (67.08 ±1.90 µmol/l, 31.18 ±5.25 µmol/l, 16 ±6.47 µmol/l, 57.00 ±7.24 UI/ml, 43.09 ±3.33 UI/ml, respectively). After 2 years of vitamin E treatment, the overall cardiovascular complications were not significantly decreased.
Conclusions:
These results showed that oral complementation with vitamin E did not affect the occurrence of cardiovascular complications associated with CKD. These findings may pave the way for future innovative strategies for antioxidant supplementation in CKD patients.
REFERENCES (50)
1.
Li PK, Garcia-Garcia G, Lui SF, et al. Kidney health for everyone, everywhere-from prevention to detection and equitable access to care. Nephrol Dialysis Transplant 2020; 35: 367-74.
2.
Yuan J, Zou XR, Han SP, et al. Prevalence and risk factors for cardiovascular disease among chronic kidney disease patients: results from the Chinese cohort study of chronic kidney disease (C-STRIDE). BMC Nephrol 2017; 18: 23.
3.
Shah R, Matthews GJ, Shah RY, et al. Serum fractalkine (CX3CL1) and cardiovascular outcomes and diabetes: findings from the Chronic Renal Insufficiency Cohort (CRIC) study. Am J Kidney Dis 2015; 66: 266-73.
4.
Ritchie J, Rainone F, Green D, et al. Extreme elevations in blood pressure and all-cause mortality in a referred CKD population: results from the CRISIS study. Int J Hypertens 2013; 2013: 597906.
5.
Zhang H, Fan L, Liao H, et al. Correlations of cardiac function with inflammation, oxidative stress and anemia in patients with uremia. Exp Ther Med 2021; 21: 250.
6.
Ataklte F, Song RJ, Upadhyay A, Musa Yola I, Vasan RS, Xanthakis V. association of mildly reduced kidney function with cardiovascular disease: the Framingham Heart Study. J Am Heart Assoc 2021; 10: 34387110.
7.
Gansevoort RT, Correa-Rotter R, Hemmelgarn BR, et al. Chronic kidney disease and cardiovascular risk: epidemiology, mechanisms, and prevention. Lancet 2013; 382: 339-52.
9.
Huang HX, Hobson K, Benedetti C, Kennedy S. Water-soluble vitamins and trace elements in children with chronic kidney disease stage 5d. Pediatr Nephrol 2024; 39: 1405-19.
10.
Trela-Makowej A, Leśkiewicz M, Kruk J, Żądło A, Basta-Kaim A, Szymańska R. Antioxidant and Neuroprotective activity of vitamin e homologues: in vitro study. Metabolites 2022; 12: 608.
11.
Weisman SJ, Lafuze JE, Haak RA, Baehner RL. Effect of vitamin E on FMLP-induced activation of rabbit polymorphonuclear leukocytes. Inflammation 2004; 11: 309-21.
13.
Zhao YW, Shi ZW. Effects of vitamin E-modified dialysis membrane on lipids in patients on hemodialysis. Arch Biol Sci 2015; 67: 503-9.
14.
Leila A, Mounir A, Abedrrezak K, Henni C, Atmene S. Revitalizing cardiac health in chronic renal failure: the synergistic effects of angiotensin-converting enzyme inhibitors and vitamin C in modulating nitric oxide and left ventricular hypertrophy. Arch Med Sci Atheroscler Dis 2023; 8: e44-52.
15.
Juvela S. Recommendations for the management of patients with unruptured intracranial aneurysms. Stroke 2001; 32: 815-6.
16.
Cohen G, Horl WH. Immune dysfunction in uremia – an update. Toxins 2012; 4: 962-90.
17.
Ikeda-Imafuku M, Fukuta T, Tuan Giam Chuang V, et al. Acute kidney injury caused by rhabdomyolysis is ameliorated by serum albumin-based supersulfide donors through antioxidative pathways. Pharmaceuticals (Basel) 2024; 18: 128.
18.
Milatović D, Zaja-Milatovic S, Gupta RC. Biomarkers of oxidative/nitrosative stress and neurotoxicity. In: Biomarkers in Toxicology. Gupta RC (ed.). Elsevier 2019; 1013-31.
19.
Urbaniak SK, Boguszewska K, Szewczuk M, Kazmierczak-Baranska J, Karwowski BT. 8-oxo-7,8-dihydro-2’-deoxyguanosine (8-oxodG) and 8-hydroxy-2’-deoxyguanosine (8-OHdG) as a potential biomarker for gestational diabetes mellitus (GDM) development. Molecules (Basel, Switzerland) 2020; 25: 202.
20.
Xu H, Watanabe M, Qureshi AR, et al. Oxidative DNA damage and mortality in hemodialysis and peritoneal dialysis patients. Perit Dial Int 2015; 35: 206-15.
21.
Beddhu S, Pappas LM, Ramkumar N, Samore MH. Malnutrition and atherosclerosis in dialysis patients. J Am Soc Nephrol 2004; 15: 733-42.
22.
Beddhu S, Kaysen GA, Yan G, et al. Association of serum albumin and atherosclerosis in chronic hemodialysis patients. Am J Kidney Dis 2002; 40: 721-7.
23.
Waziri B, Duarte R, Naicker S. Chronic kidney disease-mineral and bone disorder (CKD-MBD): current perspectives. Int J Nephrol Renovasc Dis 2019; 12: 263-76.
24.
Fishbane S, Spinowitz B. Update on anemia in ESRD and earlier stages of CKD: core curriculum 2018. Am J Kidney Dis 2018; 71: 423-35.
25.
Kramer A, Boenink R, Noordzij M, et al. The ERA-EDTA Registry Annual Report 2017: a summary. Clin Kidney J 2020; 13: 693-709.
26.
Boaz M, Matas Z, Biro A, et al. Serum malondialdehyde and prevalent cardiovascular disease in hemodialysis. Kidney Int 1999; 56: 1078-83.
27.
Chou TH, Cheng CH, Lo CJ, Young GH, Liu SH, Wang RY. New advances in rapid pretreatment for small dense LDL cholesterol measurement using shear horizontal surface acoustic wave (SH-SAW) Technology. Int J Mol Sci 2024; 25: 1044.
28.
Bayes B, Pastor MC, Bonal J, Foraster A, Romero R. Oxidative stress, inflammation and cardiovascular mortality in haemodialysis--role of seniority and intravenous ferrotherapy: analysis at 4 years of follow-up. Nephrol Dialysis Transpl 2006; 21: 984-90.
29.
Baliga KV, Sharma PK, Prakash MS, Mostafi M. Lipid profile in transplant patients: a clinical study. Med J Armed Forces India 2003; 59: 32-5.
30.
Albertini R, Moratti R, De Luca G. Oxidation of low-density lipoprotein in atherosclerosis from basic biochemistry to clinical studies. Curr Mol Med 2002; 2: 579-92.
31.
Lee CW, Li D, Channon KM, Paterson DJ. L-arginine supplementation reduces cardiac noradrenergic neurotransmission in spontaneously hypertensive rats. J Mol Cell Cardiol 2009; 47: 149-55.
32.
Janssens S, Pokreisz P, Schoonjans L, et al. Cardiomyocyte-specific overexpression of nitric oxide synthase 3 improves left ventricular performance and reduces compensatory hypertrophy after myocardial infarction. Circ Res 2004; 94: 1256-62.
33.
Sugiyama S, Okada Y, Sukhova GK, Virmani R, Heinecke JW, Libby P. Macrophage myeloperoxidase regulation by granulocyte macrophage colony-stimulating factor in human atherosclerosis and implications in acute coronary syndromes. Am J Pathol 2001; 158: 879-91.
34.
Ndrepepa G. Myeloperoxidase – a bridge linking inflammation and oxidative stress with cardiovascular disease. Clin Chim Acta 2019; 493: 36-51.
35.
Zuo C, Qiu HY, Li Z, Xie XS, Fan JM. Relationship between cardiovascular complication and inflammation, oxidative stress of patient with maintenance hemodialysis. Sichuan Da Xue Xue Bao Yi Xue Ban 2008; 39: 119-21, 29.
36.
Rehan R, Weaver J, Yong A. Coronary vasospastic angina: a review of the pathogenesis, diagnosis, and management. Life (Basel) 2022; 12: 1124.
37.
Yamadera S, Nakamura Y, Inagaki M, et al. Vitamin E-coated dialyzer inhibits oxidative stress. Blood Purification 2017; 44: 288-93.
38.
Uzum A, Toprak O, Gumustas MK, Ciftci S, Sen S. Effect of vitamin E therapy on oxidative stress and erythrocyte osmotic fragility in patients on peritoneal dialysis and hemodialysis. J Nephrol 2006; 19: 739-45.
39.
Bhogade RB, Suryakar AN, Joshi NG, Patil RY. Effect of vitamin E supplementation on oxidative stress in hemodialysis patients. Indian J Clin Biochem 2008; 23: 233-7.
40.
Roozbeh J, Shahriyari B, Akmali M, et al. Comparative effects of silymarin and vitamin E supplementation on oxidative stress markers, and hemoglobin levels among patients on hemodialysis. Ren Fail 2011; 33: 118-23.
41.
Baldi S, Innocenti M, Frascerra S, et al. Effects of hemodialysis and vitamin E supplementation on low-density lipoprotein oxidizability in end-stage renal failure. J Nephrol 2013; 26: 549-55.
42.
Kirmizis D, Papagianni A, Belechri AM, Memmos D. Effects of vitamin E-coated membrane dialyser on markers of oxidative stress and inflammation in patients on chronic haemodialysis. Nephrol Dialysis Transpl 2011; 26: 2296-301.
43.
Saini M, Vamne A, Kumar V, Chandel MS. Lipid profile in pre-dialysis and post-dialysis end stage renal disease patients: a cross-sectional comparative study in Lucknow, India. Cureus 2021; 13: 18240.
44.
Jafari T, Fallah AA, Bahrami M, Lorigooini Z. Effects of pomegranate peel extract and vitamin E on oxidative stress and antioxidative capacity of hemodialysis patients: a randomized controlled clinical trial. J Funct Foods 2020; 72: 104069.
45.
Giray B, Kan E, Bali M, Hincal F, Basaran N. The effect of vitamin E supplementation on antioxidant enzyme activities and lipid peroxidation levels in hemodialysis patients. Clin Chim Acta 2003; 338: 91-8.
46.
Galli F, Varga Z, Balla J, et al. Vitamin E, lipid profile, and peroxidation in hemodialysis patients. Kidney Int Suppl 2001; 78: S148-54.
47.
Sesso HD, Buring JE, Christen WG, et al. Vitamins E and C in the prevention of cardiovascular disease in men: the Physicians’ Health Study II randomized controlled trial. JAMA 2008; 300: 2123-33.
48.
Heart Protection Study Collaborative G. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet (London, England) 2002; 360: 7-22.
49.
Kumbhani DJ, Steg PG, Cannon CP, et al. Statin therapy and long-term adverse limb outcomes in patients with peripheral artery disease: insights from the REACH Registry. Eur Heart J 2014; 35: 2864-72.
50.
Bonaca MP, Bauersachs RM, Anand SS, et al. Rivaroxaban in peripheral artery disease after revascularization. N Engl J Med 2020; 382: 1994-2004.
Share
RELATED ARTICLE
| ISSN: | 2451-0629 |
We process personal data collected when visiting the website. The function of obtaining information about users and their behavior is carried out by voluntarily entered information in forms and saving cookies in end devices. Data, including cookies, are used to provide services, improve the user experience and to analyze the traffic in accordance with the Privacy policy. Data are also collected and processed by Google Analytics tool (more).
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
